Gene therapy trial targets glaucoma by reversing optic nerve cell aging: systemic implications for regenerative medicine and equity in healthcare access
Original framing: “Daily briefing: Trial to ‘de-age’ cells treats first person” — Nature
The trial targets glaucoma by using gene therapy to rejuvenate optic nerve cells, leveraging advances in senolytic drugs and CRISPR-based interventions. While promising, the scientific community remains cautious about off-target effects, immune responses, and the long-term stability of 'rejuvenated' cells. The study’s focus on a single condition overlooks the systemic nature of aging, which involves multiple interacting pathways (e.g., telomere shortening, mitochondrial dysfunction). Additionally, the lack of peer-reviewed data in the *Nature* briefing raises questions about the rigor of the claims, a common issue in high-profile but preliminary research.
The trial to 'de-age' optic nerve cells is emblematic of a broader neoliberal biomedical paradigm that prioritizes technological fixes over systemic change, obscuring the historical and structural forces shaping aging and healthcare.
While the science is promising, its framing by *Nature* and the biotech industry serves to reinforce a narrative of individual salvation through innovation, ignoring the colonial legacies of clinical trials, the ecological costs of gene therapies, and the cultural diversity of aging. Indigenous knowledge systems, which view aging as a relational and ecological process, offer a counterpoint to this reductionism, while marginalized communities—disproportionately affected by conditions like glaucoma—are sidelined in the rush to market. The real challenge is not just reversing cellular aging but reimagining a world where aging is met with dignity, equity, and collective care. This requires governance that balances scientific ambition with ethical and ecological responsibility, ensuring that the benefits of such breakthroughs are shared rather than hoarded by the privileged few.